1. Scrip
  2. >>Conferences
  3. >>ASCO

ASCO 2020: Can Xtandi PROSPER In Prostate OS Data Battle?

Strong Results For Rival Erleada

 
• By Ian Haydock

While Xtandi has positive new survival data in prostate cancer, other rivals in the competitive market are reporting the same at ASCO.

Prostate cancer blue ribbon_1200x675
New OS Data For Multiple Prostate Cancer Drugs At ASCO • Source: Shutterstock

Final results from the overall survival (OS) analysis of the Phase III PROSPER trial with Pfizer Inc. and Astellas Pharma Inc.’s Xtandi (enzalutamide) show the drug plus androgen deprivation therapy (ADT) significantly extended this secondary endpoint in non-metastatic castration-resistant prostate cancer (nmCRPC).

But market rival Janssen Pharmaceutical Cos.’s Erleada (apalutamide) showed an even longer extension in the same secondary endpoint in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASCO

In Brief: Sanofi Cements Support For Adagene

 
• By Kevin Grogan

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Innovent Builds Metabolic Pipeline While Retaining Oncology Backbone

 
• By Xu Hu

Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.

More from Conferences